RAFAEL HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
RAFAEL HOLDINGS, INC. (RFL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.36 million for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $1.36M, a 102.38% increase from fiscal 2024.
- RAFAEL HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $672.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-07-31 | $1.36M 10-K · filed 2025-10-29 |
| 2024-07-31 | $672.00K 10-K · filed 2025-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |